SORTIS INVEST ADVISED THE SHAREHOLDERS OF MEDICAL CENTER HERA IN THE SALE OF THE COMPANY TO FUTUREMEDS – A LANDMARK DEAL FOR THE BULGARIAN CLINICAL RESEARCH SECTOR

SORTIS INVEST ADVISED THE SHAREHOLDERS OF MEDICAL CENTER HERA IN THE SALE OF THE COMPANY TO FUTUREMEDS – A LANDMARK DEAL FOR THE BULGARIAN CLINICAL RESEARCH SECTOR

SORTIS Invest is pleased to announce its role as the exclusive financial advisor to the shareholders of Medical Center Hera EOOD and Medical Center Hera – Kyustendil EOOD (together “Hera Clinics” or “Hera”) in the sale of the companies to FutureMeds, a European network of dedicated clinical research sites backed by Phoenix Equity Partners. The […]

>> SORTIS INVEST ADVISED THE SHAREHOLDERS OF MEDICAL CENTER HERA IN THE SALE OF THE COMPANY TO FUTUREMEDS – A LANDMARK DEAL FOR THE BULGARIAN CLINICAL RESEARCH SECTOR
SORTIS Invest Advised Lexham Capital Partners On The Successful GBP 18.65 Million Fundraising For Lexham Special Opportunities I LP

SORTIS Invest Advised Lexham Capital Partners On The Successful GBP 18.65 Million Fundraising For Lexham Special Opportunities I LP

SORTIS Invest advised Lexham Capital Partners, a London-based secondaries fund manager, on the successful GBP 18.65 million  (EUR 21.5 million) fundraising for Lexham Special Opportunities I LP, which was completed on 28 August 2025. As part of the transaction, SORTIS Invest introduced and secured participation from Bulgarian investors. Lexham Special Opportunities I LP is a […]

>> SORTIS Invest Advised Lexham Capital Partners On The Successful GBP 18.65 Million Fundraising For Lexham Special Opportunities I LP